Walvax Biotech Reports Ongoing Phase III Clinical Trial Data Analysis for COVID-19 mRNA Vaccine Developed with Abogen Biosciences

Walvax Biotechnology Co., Ltd. announced on December 1st on an interactive platform that the data collation and statistical analysis work for the Phase III clinical trial of the COVID-19 mRNA vaccine, which was co-developed with Abogen Biosciences, is ongoing. The company will actively promote the market launch process of the relevant COVID-19 vaccine in accordance with the regulations and requirements of China's regulatory authorities.